[
  {
    "ts": null,
    "headline": "MHRA approves Eli Lilly’s Alzheimer’s diagnostic imaging agent Tauvid",
    "summary": "Tauvid is to be used in PET scans to identify tau buildup to better diagnose Alzheimer’s disease.",
    "url": "https://finnhub.io/api/news?id=1c8a70b744c6b2b01207e06cb01e34ef56a109fef02f62a4c5f81bb4cce43553",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732729471,
      "headline": "MHRA approves Eli Lilly’s Alzheimer’s diagnostic imaging agent Tauvid",
      "id": 131670444,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2024/10/shutterstock_2086658509-e1728382184834.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tauvid is to be used in PET scans to identify tau buildup to better diagnose Alzheimer’s disease.",
      "url": "https://finnhub.io/api/news?id=1c8a70b744c6b2b01207e06cb01e34ef56a109fef02f62a4c5f81bb4cce43553"
    }
  },
  {
    "ts": null,
    "headline": "The race for approval: oral GLP-1R therapies in obesity",
    "summary": "With expected sales estimated to exceed $126 billion by 2030, this drug category presents a lucrative market.",
    "url": "https://finnhub.io/api/news?id=a8c89a38a296c62bd7a4f024d6625d543904af8b0148b09540a3cfa9d0af24d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732727844,
      "headline": "The race for approval: oral GLP-1R therapies in obesity",
      "id": 131670134,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/shutterstock_2338582209.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With expected sales estimated to exceed $126 billion by 2030, this drug category presents a lucrative market.",
      "url": "https://finnhub.io/api/news?id=a8c89a38a296c62bd7a4f024d6625d543904af8b0148b09540a3cfa9d0af24d2"
    }
  },
  {
    "ts": null,
    "headline": "CSM: Unconvincing Long-Short ETF",
    "summary": "The ProShares Large Cap Core Plus (CSM) employs a 130/30 strategy, targeting large-cap U.S. stocks with a multi-factor model. Read the full ETF analysis here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=eb7bde2b420d0bf0d064a877741ca1135101f1d2150bc5a51abdc70bd11573ea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732723402,
      "headline": "CSM: Unconvincing Long-Short ETF",
      "id": 131672912,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286232648/image_1286232648.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The ProShares Large Cap Core Plus (CSM) employs a 130/30 strategy, targeting large-cap U.S. stocks with a multi-factor model. Read the full ETF analysis here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=eb7bde2b420d0bf0d064a877741ca1135101f1d2150bc5a51abdc70bd11573ea"
    }
  },
  {
    "ts": null,
    "headline": "LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs",
    "summary": "The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.",
    "url": "https://finnhub.io/api/news?id=0dcf457ca5d41e2c4180f3fc8d8a35787ea67be7fbc7b1eeae6c20a592591727",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732718760,
      "headline": "LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs",
      "id": 131669205,
      "image": "https://media.zenfs.com/en/zacks.com/9f505d3082c5c32dd86790426e65a15d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.",
      "url": "https://finnhub.io/api/news?id=0dcf457ca5d41e2c4180f3fc8d8a35787ea67be7fbc7b1eeae6c20a592591727"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You",
    "summary": "Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.",
    "url": "https://finnhub.io/api/news?id=6ada056afb7a7e9c6f36ad52e53f0ddc8676801915d49dd3d504b20a7f67c12f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732712818,
      "headline": "Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You",
      "id": 131670183,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304818/image_1219304818.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.",
      "url": "https://finnhub.io/api/news?id=6ada056afb7a7e9c6f36ad52e53f0ddc8676801915d49dd3d504b20a7f67c12f"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now",
    "summary": "Pharmaceutical stocks make great additions to any portfolio in any market environment.  A good one promises steady revenue growth thanks to the fact that patients need their medicines -- so will continue with them no matter what the economy is doing.  A top pharma stock also may have one particular star product that brings in blockbuster revenue, and this growth could drive stock performance.",
    "url": "https://finnhub.io/api/news?id=c0bc87ddd3c71caa11dfe9a5253774e0efc2ff9dcc9904aa58a5abedfe81cd9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732700100,
      "headline": "The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now",
      "id": 131664646,
      "image": "https://g.foolcdn.com/editorial/images/799115/scientists-high-five-smile.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks make great additions to any portfolio in any market environment.  A good one promises steady revenue growth thanks to the fact that patients need their medicines -- so will continue with them no matter what the economy is doing.  A top pharma stock also may have one particular star product that brings in blockbuster revenue, and this growth could drive stock performance.",
      "url": "https://finnhub.io/api/news?id=c0bc87ddd3c71caa11dfe9a5253774e0efc2ff9dcc9904aa58a5abedfe81cd9f"
    }
  },
  {
    "ts": null,
    "headline": "Why Amgen's Weight Loss Result Is a Win for Eli Lilly",
    "summary": "Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate.  According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.  On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable.",
    "url": "https://finnhub.io/api/news?id=6d52334313737c2e2566c814425b57af70df048f4b50e8a8fb6e5f9a57b5205f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732697820,
      "headline": "Why Amgen's Weight Loss Result Is a Win for Eli Lilly",
      "id": 131664647,
      "image": "https://g.foolcdn.com/editorial/images/799133/investor-doing-stuff-getty.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate.  According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.  On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable.",
      "url": "https://finnhub.io/api/news?id=6d52334313737c2e2566c814425b57af70df048f4b50e8a8fb6e5f9a57b5205f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
    "summary": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
    "url": "https://finnhub.io/api/news?id=8feb33640cf82775875c4286d7e6950d616e0e803074d835aad31ad703da480f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732614360,
      "headline": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
      "id": 131638489,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms",
      "url": "https://finnhub.io/api/news?id=8feb33640cf82775875c4286d7e6950d616e0e803074d835aad31ad703da480f"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Rising Dividends Fund Q3 2024 Commentary",
    "summary": "Underperformance was driven by stock selection in the information technologyÂ and financials sectors.",
    "url": "https://finnhub.io/api/news?id=a63d363879459e4dd570ae375184b2511110604effc9b6ace0ddbf0e9e8bc369",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732692000,
      "headline": "Invesco Rising Dividends Fund Q3 2024 Commentary",
      "id": 131664922,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1317087986/image_1317087986.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Underperformance was driven by stock selection in the information technologyÂ and financials sectors.",
      "url": "https://finnhub.io/api/news?id=a63d363879459e4dd570ae375184b2511110604effc9b6ace0ddbf0e9e8bc369"
    }
  },
  {
    "ts": null,
    "headline": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
    "summary": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=65fc320c0e0fa9ec65fe2a225ba6a9f92dae1916b0b065278297a418f25976fe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732691400,
      "headline": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
      "id": 131774957,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=65fc320c0e0fa9ec65fe2a225ba6a9f92dae1916b0b065278297a418f25976fe"
    }
  }
]